Marc de Garidel

Marc de Garidel – Chairman of the Board of Directors

Marc de Garidel joined Ipsen as Chairman and Chief Executive Officer in November 2010. He has been the Ipsen Chairman of the Board of Directors since July 2016.

Marc de Garidel is Chief Executive Officer and Interim Chairman of Abivax since May 2023. Prior to that, he was Chief Executive Officer and Director of CinCor Pharma Inc. between July 2021 and March 2023, company sold to Astra Zeneca in March 2023. He was previously Chief Executive Officer and Director of AZTherapies between October 2020 and May 2021. He was before that Chief Executive Officer and Director of Corvidia Therapeutics, Inc. which was sold to Novo Nordisk in July 2020.

Marc de Garidel started his career with the group Eli Lilly and pursued at Amgen, from 1995 to 2010, with increasing responsibility positions in the U.S. and Europe.

Marc de Garidel is Director of Claris Biotherapeutics since July 2020. Previously, he was Director of several biotechnology companies, including Vice Chairman of the Board of Directors of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the Board since 2015.

Marc de Garidel has a degree in Civil Engineering from the École Spéciale des Travaux Publics in Paris (ESTP), a Master’s degree in International Management (MIM) from Thunderbird Global School Management and an executive MBA from Harvard Business School.